These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32212383)

  • 1. Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells.
    Nini A; Hoffmann MJ; Lampignano R; Große Siemer R; van Dalum G; Szarvas T; Cotarelo CL; Schulz WA; Niederacher D; Neubauer H; Stoecklein NH; Niegisch G
    Cytometry B Clin Cytom; 2020 Jul; 98(4):355-367. PubMed ID: 32212383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
    Onstenk W; Kraan J; Mostert B; Timmermans MM; Charehbili A; Smit VT; Kroep JR; Nortier JW; van de Ven S; Heijns JB; Kessels LW; van Laarhoven HW; Bos MM; van de Velde CJ; Gratama JW; Sieuwerts AM; Martens JW; Foekens JA; Sleijfer S
    Mol Cancer Ther; 2015 Mar; 14(3):821-7. PubMed ID: 25552367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method.
    Chalfin HJ; Kates M; van der Toom EE; Glavaris S; Verdone JE; Hahn NM; Pienta KJ; Bivalacqua TJ; Gorin MA
    Urology; 2018 May; 115():82-86. PubMed ID: 29432873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EpCAM-expressing circulating tumor cells in colorectal cancer.
    Nicolazzo C; Raimondi C; Francescangeli F; Ceccarelli S; Trenta P; Magri V; Marchese C; Zeuner A; Gradilone A; Gazzaniga P
    Int J Biol Markers; 2017 Oct; 32(4):e415-e420. PubMed ID: 28604994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation.
    Frithiof H; Welinder C; Larsson AM; Rydén L; Aaltonen K
    J Transl Med; 2015 Apr; 13():126. PubMed ID: 25896421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.
    Königsberg R; Obermayr E; Bises G; Pfeiler G; Gneist M; Wrba F; de Santis M; Zeillinger R; Hudec M; Dittrich C
    Acta Oncol; 2011 Jun; 50(5):700-10. PubMed ID: 21261508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.
    Le Du F; Fujii T; Kida K; Davis DW; Park M; Liu DD; Wu W; Chavez-MacGregor M; Barcenas CH; Valero V; Tripathy D; Reuben JM; Ueno NT
    PLoS One; 2020; 15(3):e0229903. PubMed ID: 32214335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test.
    Adams DL; Stefansson S; Haudenschild C; Martin SS; Charpentier M; Chumsri S; Cristofanilli M; Tang CM; Alpaugh RK
    Cytometry A; 2015 Feb; 87(2):137-44. PubMed ID: 25515318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer.
    Schneck H; Gierke B; Uppenkamp F; Behrens B; Niederacher D; Stoecklein NH; Templin MF; Pawlak M; Fehm T; Neubauer H;
    PLoS One; 2015; 10(12):e0144535. PubMed ID: 26695635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma.
    Flaig TW; Wilson S; van Bokhoven A; Varella-Garcia M; Wolfe P; Maroni P; Genova EE; Morales D; Lucia MS
    Urology; 2011 Oct; 78(4):863-7. PubMed ID: 21813167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance).
    Magbanua MJM; Rugo HS; Wolf DM; Hauranieh L; Roy R; Pendyala P; Sosa EV; Scott JH; Lee JS; Pitcher B; Hyslop T; Barry WT; Isakoff SJ; Dickler M; Van't Veer L; Park JW
    Clin Cancer Res; 2018 Mar; 24(6):1486-1499. PubMed ID: 29311117
    [No Abstract]   [Full Text] [Related]  

  • 12. Association of preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection.
    Zhou Y; Wang B; Wu J; Zhang C; Zhou Y; Yang X; Zhou J; Guo W; Fan J
    BMC Cancer; 2016 Jul; 16():506. PubMed ID: 27439521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial.
    Jaeger BAS; Neugebauer J; Andergassen U; Melcher C; Schochter F; Mouarrawy D; Ziemendorff G; Clemens M; V Abel E; Heinrich G; Schueller K; Schneeweiss A; Fasching P; Beckmann MW; Scholz C; Friedl TWP; Friese K; Pantel K; Fehm T; Janni W; Rack B
    PLoS One; 2017; 12(6):e0173593. PubMed ID: 28586395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of miR-21 with Circulating Tumor Cells Markers Improve Diagnostic Specificity of Metastatic Breast Cancer.
    Yang X; Wang X; Shen H; Deng R; Xue K
    Cell Biochem Biophys; 2015 Sep; 73(1):87-91. PubMed ID: 25669446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and verification of a three-dimensional (3D) breast cancer tumor model composed of circulating tumor cell (CTC) subsets.
    Anil-Inevi M; Sağlam-Metiner P; Kabak EC; Gulce-Iz S
    Mol Biol Rep; 2020 Jan; 47(1):97-109. PubMed ID: 31583566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Workflow to Enrich and Isolate Patient-Matched EpCAM
    Lampignano R; Yang L; Neumann MHD; Franken A; Fehm T; Niederacher D; Neubauer H
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28858218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular biomarker analyses using circulating tumor cells.
    Punnoose EA; Atwal SK; Spoerke JM; Savage H; Pandita A; Yeh RF; Pirzkall A; Fine BM; Amler LC; Chen DS; Lackner MR
    PLoS One; 2010 Sep; 5(9):e12517. PubMed ID: 20838621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating CEA-positive and EpCAM-negative tumor cells might be a predictive biomarker for recurrence in patients with gastric cancer.
    Miki Y; Yashiro M; Kuroda K; Okuno T; Togano S; Masuda G; Kasashima H; Ohira M
    Cancer Med; 2021 Jan; 10(2):521-528. PubMed ID: 33381922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer.
    Nanou A; Zeune LL; Bidard FC; Pierga JY; Terstappen LWMM
    Breast Cancer Res; 2020 Aug; 22(1):86. PubMed ID: 32787900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A New Cell Block Method for Multiple Immunohistochemical Analysis of Circulating Tumor Cells in Patients with Liver Cancer.
    Nam SJ; Yeo HY; Chang HJ; Kim BH; Hong EK; Park JW
    Cancer Res Treat; 2016 Oct; 48(4):1229-1242. PubMed ID: 27034142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.